Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Eur J Cancer
    September 2021
  1. MATSUO K, Klar M, Mohrbacher AF, Roman LD, et al
    Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
    Eur J Cancer. 2021;157:59-62.
    >> Share

    August 2021
  2. KAHAN Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, et al
    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Eur J Cancer. 2021;156:70-82.
    >> Share

  3. JOHANSSON ALV, Fredriksson I, Mellemkjaer L, Stensheim H, et al
    Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018.
    Eur J Cancer. 2021;155:106-115.
    >> Share

    July 2021
  4. TJOKROWIDJAJA A, Friedlander M, Lord SJ, Asher R, et al
    Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
    Eur J Cancer. 2021;154:190-200.
    >> Share

    June 2021
  5. FURLANETTO J, Marme F, Seiler S, Thode C, et al
    Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Eur J Cancer. 2021;152:193-203.
    >> Share

  6. BERGAMINI A, Sarwar N, Ferrandina G, Scarfone G, et al
    Response to the Letter to the Editor by Lockley et al. commenting on 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis'.
    Eur J Cancer. 2021 Jun 7. pii: S0959-8049(21)00284.
    >> Share

  7. LOCKLEY M, Stoneham S, Shamash J, Pashankar F, et al
    Re: 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis'.
    Eur J Cancer. 2021 Jun 4. pii: S0959-8049(21)00283.
    >> Share

    May 2021
  8. KIM HJ, Noh WC, Nam SJ, Park BW, et al
    Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Eur J Cancer. 2021;151:190-200.
    >> Share

  9. WENZEL HHB, Bekkers RLM, Lemmens VEPP, Van der Aa MA, et al
    No improvement in survival of older women with cervical cancer-A nationwide study.
    Eur J Cancer. 2021;151:159-167.
    >> Share

    April 2021
  10. SOUKUPOVA J, Zemankova P, Nehasil P, Kleibl Z, et al
    Letter to the Editor: Comments on ERCC3 as a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 21. pii: S0959-8049(21)00181.
    >> Share

  11. STRADELLA A, Del Valle J, Brunet J, Lazaro C, et al
    Response to letter re: ERCC3 a new ovarian cancer susceptibility gene.
    Eur J Cancer. 2021 Apr 19. pii: S0959-8049(21)00182.
    >> Share

    March 2021
  12. MATHEVET P, Lecuru F, Uzan C, Boutitie F, et al
    Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).
    Eur J Cancer. 2021;148:307-315.
    >> Share

  13. FRANCIS KE, Gebski V, Lord SJ, Friedlander M, et al
    Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event repor
    Eur J Cancer. 2021;148:251-259.
    >> Share

  14. SEPPALA TT, Dominguez-Valentin M, Crosbie EJ, Engel C, et al
    Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    Eur J Cancer. 2021;148:124-133.
    >> Share

  15. MATSUO K, Shimada M, Matsuzaki S, Enomoto T, et al
    Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic.
    Eur J Cancer. 2021;148:117-120.
    >> Share

  16. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    >> Share

    January 2021
  17. FALCONER H, Yin L, Salehi S, Altman D, et al
    Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer.
    Eur J Cancer. 2021;145:38-43.
    >> Share

  18. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
    Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Eur J Cancer. 2021;145:19-28.
    >> Share

    December 2020
  19. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Eur J Cancer. 2020;144:341-350.
    >> Share

  20. FERRANDINA G, Aristei C, Biondetti PR, Cananzi FCM, et al
    Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168].
    Eur J Cancer. 2020 Dec 19. pii: S0959-8049(20)31301.
    >> Share

  21. DITTO A, Casarin J, Pinelli C, Perrone AM, et al
    Corrigendum to "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group" [European Journa
    Eur J Cancer. 2020 Dec 17. pii: S0959-8049(20)31355.
    >> Share

  22. CIBULA D, Dostalek L, Hillemanns P, Scambia G, et al
    Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.
    Eur J Cancer. 2020;143:88-100.
    >> Share

    November 2020
  23. DAFNI U, Martin-Lluesma S, Balint K, Tsourti Z, et al
    Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    Eur J Cancer. 2020;142:63-82.
    >> Share

  24. RESTAINO S, Tortorella L, Dinoi G, Zannoni GF, et al
    Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications.
    Eur J Cancer. 2020;142:29-37.
    >> Share

  25. KANG S, Yu YL, Cho SY, Park SY, et al
    Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
    Eur J Cancer. 2020;141:185-192.
    >> Share

  26. MATSUO K, Wright JD, Matsuzaki S, Roman LD, et al
    Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence.
    Eur J Cancer. 2020;140:149-150.
    >> Share

    October 2020
  27. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    >> Share

  28. DITTO A, Casarin I, Perrone AM, Scollo P, et al
    Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group.
    Eur J Cancer. 2020;140:1-10.
    >> Share

    September 2020
  29. MATSUO K, Huang Y, Matsuzaki S, Klar M, et al
    Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic.
    Eur J Cancer. 2020;139:173-176.
    >> Share

  30. FERRANDINA G, Cynthia A, Raimondo BP, Maria CFC, et al
    Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
    Eur J Cancer. 2020;139:149-168.
    >> Share

  31. BISCH S, Nelson G
    Randomised controlled trial confirms benefit of enhanced recovery after surgery on length of stay in ovarian cancer: How low can we go?
    Eur J Cancer. 2020;139:90-91.
    >> Share

  32. TJOKROWIDJAJA A, Lee CK, Friedlander M, Gebski V, et al
    Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    Eur J Cancer. 2020;139:59-67.
    >> Share

  33. PINELLI C, Bogani G, Casarin J, Raspagliesi F, et al
    Malignant peritoneal cytology in endometrial cancer.
    Eur J Cancer. 2020 Sep 10. pii: S0959-8049(20)30449.
    >> Share

    August 2020
  34. VANDENBROUCKE T, Verheecke M, van Gerwen M, Van Calsteren K, et al
    Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy.
    Eur J Cancer. 2020;138:57-67.
    >> Share

  35. JANSEN EEL, Zielonke N, Gini A, Anttila A, et al
    Response to the letter commenting on 'Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review'.
    Eur J Cancer. 2020 Aug 15. pii: S0959-8049(20)30395.
    >> Share

  36. BERGAMINI A, Sarwar N, Ferrandina G, Scarfone G, et al
    Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis.
    Eur J Cancer. 2020;137:136-143.
    >> Share

  37. CIBULA D, Kocian R, Plaikner A, Jarkovsky J, et al
    Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial.
    Eur J Cancer. 2020;137:69-80.
    >> Share

    July 2020
  38. KITSON SJ, Bafligil C, Ryan NAJ, Lalloo F, et al
    BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    Eur J Cancer. 2020;136:169-175.
    >> Share

  39. SANCHEZ-IGLESIAS JL, Carbonell-Socias M, Perez-Benavente MA, Monreal Clua S, et al
    PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
    Eur J Cancer. 2020;136:149-158.
    >> Share

  40. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 14. pii: S0959-8049(20)30339.
    >> Share

  41. HOWELL SJ, Keevil B, Higham C, Owen LJ, et al
    RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 11. pii: S0959-8049(20)30338.
    >> Share

    June 2020
  42. MASTELIC-GAVILLET B, Sarivalasis A, Lozano LE, Wyss T, et al
    Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
    Eur J Cancer. 2020;135:173-182.
    >> Share

  43. DUGUE PA, Lynge E, Rebolj M
    Comment on 'Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review'.
    Eur J Cancer. 2020 Jun 12. pii: S0959-8049(20)30236.
    >> Share

    May 2020
  44. VAN WEELDEN WJ, Reijnen C, Eggink FA, Boll D, et al
    Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
    Eur J Cancer. 2020;133:104-111.
    >> Share

  45. CHOI MC, Chung YS, Lee JW, Kwon BS, et al
    Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Eur J Cancer. 2020;133:56-65.
    >> Share

  46. MATSUO K, Matsuzaki S, Nusbaum DJ, Machida H, et al
    Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.
    Eur J Cancer. 2020;133:33-46.
    >> Share

  47. WENZEL HHB, Smolders RGV, Beltman JJ, Lambrechts S, et al
    Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review.
    Eur J Cancer. 2020;133:14-21.
    >> Share

    April 2020
  48. LOK C, van Trommel N, Massuger L, Golfier F, et al
    Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease.
    Eur J Cancer. 2020;130:228-240.
    >> Share

    March 2020
  49. BERNEY DM, Shamash J, Stoneham S, Lockley M, et al
    Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 18. pii: S0959-8049(20)30048.
    >> Share

  50. ONDA T, Satoh T, Ogawa G, Saito T, et al
    Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Eur J Cancer. 2020;130:114-125.
    >> Share

  51. PASHANKAR F, Frazier AL
    Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2020 Mar 13. pii: S0959-8049(20)30047.
    >> Share

  52. CRISCITIELLO C, Curigliano G
    Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    Eur J Cancer. 2020;127:236-239.
    >> Share

  53. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    >> Share

    February 2020
  54. JENSEN PT, Schnack TH, Froding LP, Bjorn SF, et al
    Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer - A population-based study.
    Eur J Cancer. 2020;128:47-56.
    >> Share

    January 2020
  55. JANSEN EEL, Zielonke N, Gini A, Anttila A, et al
    Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.
    Eur J Cancer. 2020 Jan 21. pii: S0959-8049(19)30868.
    >> Share

  56. BAGRATUNI T, Mavrianou N, Gavalas NG, Tzannis K, et al
    JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Eur J Cancer. 2020;126:125-135.
    >> Share

  57. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020;126:104-105.
    >> Share

  58. WOJTYLA C, Janik-Koncewicz K, La Vecchia C
    Cervical cancer mortality in young adult European women.
    Eur J Cancer. 2020;126:56-64.
    >> Share

    December 2019
  59. RUSAN M, Andersen RF, Jakobsen A, Steffensen KD, et al
    Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
    Eur J Cancer. 2019;125:121-129.
    >> Share

    November 2019
  60. FLAUM N, Crosbie EJ, Woodward ER, Lalloo F, et al
    Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants.
    Eur J Cancer. 2019;124:88-90.
    >> Share

  61. LOOPIK DL, IntHout J, Melchers WJG, Massuger LFAG, et al
    Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study.
    Eur J Cancer. 2019;124:102-109.
    >> Share

    September 2019
  62. CHOI MC, Oh J, Lee C
    Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;121:94-97.
    >> Share

    July 2019
  63. VAN DER HEL OL, Timmermans M, van Altena AM, Kruitwagen RFPM, et al
    Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
    Eur J Cancer. 2019;118:97-104.
    >> Share

  64. DEPANI S, Stoneham S, Krailo M, Xia C, et al
    Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII).
    Eur J Cancer. 2019;118:49-57.
    >> Share

  65. LEE CK, Asher R, Friedlander M, Gebski V, et al
    Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    Eur J Cancer. 2019;117:99-106.
    >> Share

    June 2019
  66. ALFONZO E, Wallin E, Ekdahl L, Staf C, et al
    No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study.
    Eur J Cancer. 2019;116:169-177.
    >> Share

  67. PERSSON J, Salehi S, Bollino M, Lonnerfors C, et al
    Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging.
    Eur J Cancer. 2019;116:77-85.
    >> Share

  68. ROUSSET-JABLONSKI C, Selle F, Adda-Herzog E, Planchamp F, et al
    Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers.
    Eur J Cancer. 2019;116:35-44.
    >> Share

  69. PERRONE F, De Laurentiis M, De Placido S, Orditura M, et al
    Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297.
    >> Share

    May 2019
  70. FROEHLICH K, Schmidt A, Heger JI, Al-Kawlani B, et al
    Breast cancer, placenta and pregnancy.
    Eur J Cancer. 2019;115:68-78.
    >> Share

    April 2019
  71. NEWTON C, Murali K, Ahmad A, Hockings H, et al
    A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Eur J Cancer. 2019;113:19-27.
    >> Share

    February 2019
  72. DELLE MARCHETTE M, Ceppi L, Andreano A, Bonazzi CM, et al
    Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.
    Eur J Cancer. 2019;111:61-68.
    >> Share

  73. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    >> Share

  74. FRIJSTEIN MM, Lok CAR, Short D, Singh K, et al
    The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia.
    Eur J Cancer. 2019;109:162-171.
    >> Share

    January 2019
  75. JORGENSEN SL, Mogensen O, Wu CS, Korsholm M, et al
    Survival after a nationwide introduction of robotic surgery in women with early-stage endometrial cancer: a population-based prospective cohort study.
    Eur J Cancer. 2019;109:1-11.
    >> Share

    November 2018
  76. MENZER C, Beedgen B, Rom J, Duffert CM, et al
    Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
    Eur J Cancer. 2018;104:239-242.
    >> Share

    September 2018
  77. CAMPONE M, Im SA, Iwata H, Clemons M, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    Eur J Cancer. 2018;103:147-154.
    >> Share

    July 2018
  78. BOUVARD B, Chatelais J, Soulie P, Hoppe E, et al
    Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
    Eur J Cancer. 2018;101:87-94.
    >> Share

  79. BRETTHAUER M, Goderstad JM, Loberg M, Emilsson L, et al
    Uterine morcellation and survival in uterine sarcomas.
    Eur J Cancer. 2018;101:62-68.
    >> Share

  80. HESCOT S, Haissaguerre M, Pautier P, Kuhn E, et al
    Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.
    Eur J Cancer. 2018;97:57-58.
    >> Share

    June 2018
  81. MEYS EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, et al
    Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer.
    Eur J Cancer. 2018;100:55-64.
    >> Share

    May 2018
  82. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    >> Share

  83. MANDALA M, Merelli B, Indriolo A, Tondini C, et al
    Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
    Eur J Cancer. 2018;95:130-132.
    >> Share

    April 2018
  84. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    >> Share

  85. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Eur J Cancer. 2018;95:59-67.
    >> Share

  86. PLOQUIN A, Pistilli B, Tresch E, Frenel JS, et al
    5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.
    Eur J Cancer. 2018;95:30-37.
    >> Share

  87. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    >> Share

    January 2018
  88. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    >> Share

  89. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    >> Share

    November 2017
  90. TIMMERMANS M, Sonke GS, Van de Vijver KK, van der Aa MA, et al
    No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.
    Eur J Cancer. 2017;88:31-37.
    >> Share

  91. TEMKIN SM, Miller EA, Samimi G, Berg CD, et al
    Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Eur J Cancer. 2017;87:182-188.
    >> Share

  92. ANDERSON RA, Mansi J, Coleman RE, Adamson DJA, et al
    The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Eur J Cancer. 2017;87:58-64.
    >> Share

    October 2017
  93. VERSLUIS MAC, Marchal S, Plat A, de Bock GH, et al
    The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
    Eur J Cancer. 2017;86:285-295.
    >> Share

  94. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    >> Share

    September 2017
  95. VANDERSTICHELE A, Busschaert P, Olbrecht S, Lambrechts D, et al
    Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2017;86:5-14.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016